Mekinist (trametinib) / Novartis, Japan Tobacco, BeiGene 
Welcome,         Profile    Billing    Logout  

195 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mekinist (trametinib) / Novartis, BeiGene
NCT03919071: Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

Recruiting
2
58
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Lumbar Puncture, LP, Spinal Tap, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Trametinib Dimethyl Sulfoxide, Mekinist, Meqsel, Spexotras
National Cancer Institute (NCI)
Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma, Glioblastoma, Malignant Glioma, WHO Grade 3 Glioma
09/27
09/27
PLGG - MEKTRIC, NCT05180825: Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy

Recruiting
2
134
Europe
Trametinib, Vinblastine
University Hospital, Strasbourg, France
Grade 1 Glioma, Mixed Glio-neuronal Tumors, Pleomorphic Xanthoastrocytoma
11/31
12/31
2021-003398-79: International study in which the idea is to use the abnormalities of the bloodtumor of children, that is either not responsive to standard therapy or has returned, as a starting point for a new therapy. Internationale studie waarin het idee is om de afwijkingen van de bloedtumor bij kinderen, die of ongevoelig is voor standaard therapie of die is teruggekomen, te gebruiken als vertrekpunt voor een nieuwe behandeling.

Not yet recruiting
1/2
26
Europe
Trametinib, TMT212, Film-coated tablet, Powder for oral solution, Mekinist
Princess Máxima Center for pediatric oncology, European Science Foundation - Fight Kids Cancer
Molecularly profiled r/r ALL/LBL whose tumor harbors an actionable event that can be targeted by the investigational agents. In this subprotocol, patients must present alterations in the RAS signaling pathway. Moleculaire geprofileerde r/r/ ALL/LBL waarvan de tumor een target heeft voor de onderzoeksmedicatie. In dit sub-protocol moet de tumor een verandering hebben in de RAS signaal transductie route., relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) with activating mutations of the RAS signaling pathway recidief of refractaire acute lymfatische leukemie (ALL) of lymfoblastisch lymfoom(LL) met activerende mutaties van het RAS-signaalpad., Diseases [C] - Cancer [C04]
 
 
2019-001399-13: MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable NRAS Melanoma: A Phase Ib/II Trial of Trametinib plus Hydroxychloroquine in Patients with NRAS Melanoma. CHLORO TRAM MEL Etude de phase I/II évaluant la tolérance d’un traitement par hydroxychloroquine associé au tramétinib dans le mélanome NRAS muté métastatique ou localement avancé non résécable après échec d’une immunothérapie. CHLORO TRAM MEL

Not yet recruiting
1/2
29
Europe
Trametinib, Sulfate d'hydroxychloroquine, Tablet, Mekinist, Plaquenil
Hospices Civils de Lyon, Health ministry, Novartis
Patients with metastatic NRAS melanoma, Patients with metastatic NRAS melanoma, Diseases [C] - Cancer [C04]
 
 
2014-002209-39: Phase I/II study with lapatinib plus trametinib in patients with metastatic non-small cell lung cancer with a mutation in the KRAS gene Fase I/II studie met de combinatie van lapatinib met trametinib bij patiënten met uitgezaaid niet kleincellig longkanker met een KRAS genmutatie

Ongoing
1/2
132
Europe
Lapatinib, trametinib, docetaxel, Tablet, Film-coated tablet, Concentrate and solvent for concentrate for solution for infusion, Mekinist
The Netherlands Cancer Institute, Novartis
non-small cell lung cancer niet-kleincellig longkanker, lung cancer longkanker, Diseases [C] - Cancer [C04]
 
 
NCT01970956: Dabrafenib/Trametinib/Navitoclax In Braf Mutant Melanoma

Not yet recruiting
1/2
18
US
Navitoclax, ABT-263, Dabrafenib, GSK2118436, GSK2118436A (free base), Tafinlar, Trametinib, GSK1120212, JTP-74057, JTP-78296, JTP-75303, Mekinist
Massachusetts General Hospital, National Cancer Institute (NCI)
BRAF Mutant Melanoma, Solid Tumors
01/17
09/20
SWOG-S1221, NCT01902173: Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Active, not recruiting
1/2
27
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Trametinib Dimethyl Sulfoxide, Mekinist, Meqsel, Uprosertib, GSK2141795, Oral Akt Inhibitor GSK2141795
National Cancer Institute (NCI), GlaxoSmithKline, Novartis Pharmaceuticals
Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma
05/18
10/24
2019-004819-31: First in human study assessing the safety, immunogenicity and efficacy of the cancer vaccine IN01 as second line of treatment in RAS and BRAF mutated metastatic colorectal cancer patients

Not yet recruiting
1/2
70
Europe
trametinib, encorafenib, IN01, Emulsion and suspension for emulsion for injection, Tablet, Capsule, hard, MEKINIST, BRAFTOVI
IN3BIO, IN3BIO
colorectal cancer at a metastatic stage, eligible for a second line treatment and presenting with a constitutive BRAF or RAS mutation, patients with a colorectal cancer with distant metastasis and laboratory identified BRAF or RAS constitutive tumour mutations eligible to receive a second line treatment, Diseases [C] - Cancer [C04]
 
 
2021-006196-42: Study of JDQ443 , in combination with trametinib or ribociclib or cetuximab, in advanced cancer with a specific mutation (changes in a gene) called KRAS G12C

Not yet recruiting
1/2
450
Europe
JDQ443, TMT212, ribociclib, cetuximab, JDQ443, TMT212, LEE011, Tablet, Film-coated tablet, Solution for infusion, Mekinist, Kisqali, Erbitux
Novartis Pharma AG, NOVARTIS PHARMA AG, Novartis Farmacéutica, S.A., Novartis Pharma AG
adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors, advanced cancer with a specific mutation (G12C) in the KRAS gene, Diseases [C] - Cancer [C04]
 
 
2021-005167-51: A trial to determine the safety of CC-92480 when combined with novel compounds in people who have Multiply Myeloma that is not responsive after treatment or has returned after a period of treatment Un ensayo para determinar la seguridad de CC-92480 cuando se combina con compuestos novedosos en personas con mieloma múltiple que no responde después del tratamiento o ha regresado después de un período de tratamiento

Not yet recruiting
1/2
60
Europe
CC-92480, BET-Inhibitor, Tazemetostat (Tazverik), Trametinib Mekinist, Dexamethasone, BMS-986158, TMT212, Capsule, hard, Capsule, Tablet, Tazemetostat (Tazverik), Trametinib Mekinist
Celgene Corporation, Celgene Corporation
Relapsed or Refractory Multiple Myeloma (RRMM) Mieloma múltiple recidivante o resistente (MMRR), Cancer of plasma cells Cancer de células plasmáticas, Diseases [C] - Cancer [C04]
 
 
TRIDENT-2, NCT05071183: A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Hourglass Jan 2023 - Dec 2023 : Data readout from P1b/2 TRIDENT-2 trial in combination with trametinib for KRAS mutant solid tumors
Terminated
1/2
9
US
TPX-0005, repotrectinib, Trametinib, Mekinist
Turning Point Therapeutics, Inc.
KRAS Mutation-Related Tumors, Metastatic Solid Tumor, Advanced Solid Tumor
03/23
03/23
NCT04326283: Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated
1/2
23
RoW
Trametinib (0.5 mg), Meqsel, SNR1611, Trametinib (1 mg), Riluzole (100 mg), Yooritek
Genuv Inc.
Amyotrophic Lateral Sclerosis
04/23
04/23
NCT02079740: Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
97
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Navitoclax, A-855071.0, ABT-263, BcI-2 Family Protein Inhibitor ABT-263, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Trametinib, GSK 1120212, GSK-1120212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212
National Cancer Institute (NCI)
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
12/22
03/25
NCI-2013-02103, NCT01989585: Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

Active, not recruiting
1/2
75
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dabrafenib, BRAF Inhibitor GSK2118436, GSK 2118436, GSK 2118436A, GSK-2118436, GSK-2118436A, GSK2118436, GSK2118436A, Echocardiography, EC, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Navitoclax, A-855071.0, ABT-263, BcI-2 Family Protein Inhibitor ABT-263, Pharmacological Study, Trametinib, GSK 1120212, GSK 212, GSK-1120212, GSK-212, GSK1120212, GSK212, JTP 74057, JTP-74057, JTP74057, MEK Inhibitor GSK1120212
National Cancer Institute (NCI)
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm, Metastatic Melanoma, Unresectable Melanoma
12/24
12/24
CheckMate 9N9, NCT03377361 / 2017-001830-24: An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread

Active, not recruiting
1/2
232
Europe, Canada, US, RoW
Nivolumab, Opdivo, BMS-936558, Trametinib, Mekinist, Ipilimumab, Yervoy, BMS-734016, Regorafenib
Bristol-Myers Squibb, Novartis
Colorectal Cancer, Colorectal Tumors, Colorectal Carcinoma, Colorectal Neoplasm
03/24
03/24
NCT04892017: A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors

Recruiting
1/2
173
US
DCC-3116, Trametinib, Binimetinib, Sotorasib
Deciphera Pharmaceuticals LLC
Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
08/27
08/28
2015-002615-15: A comparison of the effects of standard melanoma treatment in combination with BGB324, an investigational agent, to standard treatment alone

Not yet recruiting
1/2
92
Europe
BGB324, Capsule, hard, Powder for infusion, Film-coated tablet, Concentrate for solution for infusion, Keytruda, Tafinlar, Mekinist
Helse Bergen HF, Haukeland universitetssjukehus, Kreftforeningen, BerGenBio, KLINBEFORSK
Advanced non-resectable (Stage IIIc) or metastatic (Stage IV) melanoma, Melanoma, the most Dangerous form of skin cancer, Diseases [C] - Cancer [C04]
 
 
NCT02143050: Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients

Withdrawn
1/2
53
US
Dabrafenib, Tafinlar, Trametinib, Mekinist, Metformin, Glucophage
University of Louisville, James Graham Brown Cancer Center
Melanoma
11/17
11/17
NCT02872259: BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

Checkmark Updated results in combination with dabrafenib/trametinib/pembrolizumab for metastatic melanoma
Oct 2018 - Oct 2018: Updated results in combination with dabrafenib/trametinib/pembrolizumab for metastatic melanoma
Checkmark Presentation of combination study with Tafinlar and BGB324 at ASCO 2018
Jun 2018 - Jun 2018: Presentation of combination study with Tafinlar and BGB324 at ASCO 2018
Completed
1/2
74
Europe
BGB324+pembrolizumab, Keytruda, BGB324+dabrafenib and trametinib, Tafinlar, Mekinist, pembrolizumab, dabrafenib and trametinib
Haukeland University Hospital, BerGenBio ASA
Melanoma
05/24
05/24
NCT06456138: Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Not yet recruiting
1/2
60
RoW
Trametinib, Anlotinib, Tislelizumab
Shanghai Chest Hospital, BeiGene, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Novartis
KRAS Mutation-Related Tumors, Advanced Lung Cancer, Refractory Tumor
06/26
12/28
NCT03455764: MCS110 With BRAF/MEK Inhibition in Patients With Melanoma

Active, not recruiting
1/2
43
US
MCS110, Dabrafenib, Tafinlar, Trametinib, Mekinist
Dana-Farber Cancer Institute, Novartis
Melanoma
09/24
09/25
ENHANCE, NCT05275374: XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

Not yet recruiting
1/2
221
NA
XP-102, Trametinib
Xynomic Pharmaceuticals, Inc.
Cancer, BRAF V600 Mutation, Melanoma, Colorectal Cancer, Thyroid Cancer, Nonsmall Cell Lung Cancer
12/25
12/26
NCT04557956: Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

Recruiting
1/2
58
US
Biopsy, BIOPSY_TYPE, Bx, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Echocardiogram Recording, Echocardiogram, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Tazemetostat Hydrobromide, EPZ-6438 Monohydrobromide, Tazemetostat Monohydrobromide, TAZVERIK, Trametinib Dimethyl Sulfoxide, Mekinist, Meqsel, Spexotras
National Cancer Institute (NCI)
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
12/24
12/24
IM-BATTLE-2 Program, NCT03225664: Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

Active, not recruiting
1/2
37
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pharmacokinetic Study, PHARMACOKINETIC, PK Study, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
12/24
12/24
NCT05874414: Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutation Cholangiocarcinoma

Recruiting
1/2
74
US
GNS561 + Trametinib, Ezurpimtrostat (GNS561)
Genfit
Cholangiocarcinoma
05/26
10/26
NCT05677373: Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma

Withdrawn
1/2
54
NA
BRD4 Inhibitor PLX2853, PLX 2853, PLX-2853, PLX2853, Trametinib, 871700-17-3, GSK1120212, JTP-74057, Computed Tomography, CAT, CAT scan, Computed Axial Tomography, CT Scan, Magnetic Resonance Imaging, MRI, Biospecimen collection
Alliance for Clinical Trials in Oncology
Advanced Uveal Melanoma, Metastatic Uveal Melanoma, Unresectable Uveal Melanoma
07/25
07/25
NCT04201457: A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

Recruiting
1/2
75
US
Dabrafenib, Dabrafenib mesylate, Tafinlar, Trametinib, Trametinib dimethyl sulfoxide, Mekinist, Hydroxychloroquine, Plaquenil, Plaquinol, Toremonil, Ercoquinn
Pediatric Brain Tumor Consortium, National Cancer Institute (NCI), American Lebanese Syrian Associated Charities (ALSAC)
Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1
08/26
06/29
CA057-003, NCT05372354: A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
1/2
220
Europe, Canada, US
CC-92480, BMS-986348, Tazemetostat, BMS-986158, Trametinib, Dexamethasone
Bristol-Myers Squibb
Multiple Myeloma
10/26
10/26
NCT05668585: A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

Recruiting
1/2
206
Europe, US
CFT1946, Trametinib, Cetuximab
C4 Therapeutics, Inc.
Solid Tumors, Melanoma, NSCLC, CRC, ATC
03/27
04/27
KontRASt-03, NCT05358249: Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Recruiting
1/2
346
Europe, US, RoW
JDQ443, trametinib, TMT212, Ribociclib, LEE011, cetuximab
Novartis Pharmaceuticals
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Colorectal Cancer, Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumors, Neoplasms, Colorectal
05/27
06/27
NCT05849662: A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Recruiting
1/2
58
US
Trametinib, GSK1120212B, TMT212-NXA, Azacitidine, 5-azacytidine, Vidaza, Fludarabine, FLUDARA FOR INJECTION, Cytarabine, Cytosine arabinoside, Ara-C, Cytosar
Therapeutic Advances in Childhood Leukemia Consortium
Leukemia, Juvenile Myelomonocytic, JMML, JCML, Neurofibromatosis 1, CBL Syndrome
12/28
12/29
HEM-iSMART D, NCT05658640: HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

Recruiting
1/2
26
Europe
Trametinib, Dexamethasone, Cyclophosphamide, Cytarabine, Intrathecal chemotherapy
Princess Maxima Center for Pediatric Oncology, Innovative Therapies For Children with Cancer Consortium, IBFM, Fight Kids Cancer
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
04/29
04/29
NCT03088176: Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

Active, not recruiting
1b
4
US
Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil, Imlygic, Talimogene Laherparep 100 Mil Pfu/Ml 1Ml, Dabrafenib, Tafinlar, Trametinib, Mekinist
West Cancer Center, University of Tennessee Health Science Center, Amgen
Melanoma, BRAF Gene Mutation
11/20
06/21
NCT02007382: Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction

Recruiting
1
68
US, Canada
Trametinib, GSK1120212
University Health Network, Toronto, National Cancer Institute (NCI)
Solid Tumors, Hepatic Dysfunction
06/15
12/15
2011-004901-25: A study to compare the tablet and oral solution formulations of GSK1120212 in cancer patients

 
1
18
NA
GSK1120212,
GlaxoSmithKline Research and Development Ltd, GSK
GSK1120212 is currently being developed for a number of solid tumors, including metastatic BRAF-mutant melanoma (Phase 3), pancreatic cancer (Phase 2) and non small cell lung cancer (Phase 2), and in hematological malignancies, including acute-myeloid leukemia (AML) or chronic myelo-monocytic leukemia (CMML).
 
 
NCT01938703: BRAF-MEK INHIBITORS IN SEQUENCE WITH IPILIMUMAB FOR BRAF MUTANT MELANOMA

Recruiting
1
40
US
Dabrafenib, Trametinib, Ipilimumab
Dana-Farber Cancer Institute, National Cancer Institute (NCI), National Institutes of Health (NIH)
Malignant Melanoma, Cutaneous Neoplasms
12/16
08/19
NCT01912625: Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Terminated
1
16
US
3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D Conformal, 3D CONFORMAL RADIATION THERAPY, 3D CRT, 3D radiotherapy, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Radiation, 3D Conformal, Three dimensional external beam radiation therapy (procedure), Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Image Guided Radiation Therapy, IGRT, image-guided radiation therapy, Image-Guided Radiotherapy, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pharmacological Study, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212
National Cancer Institute (NCI)
Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
11/17
02/23
NCT02097225: Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Active, not recruiting
1
22
US
Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Laboratory Biomarker Analysis, Onalespib, AT 13387, AT-13387, AT13387, Pharmacological Study, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212
National Cancer Institute (NCI)
BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Solid Neoplasm
03/19
 
NCT03272464: INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

Terminated
1
1
US
Trametinib, Mekinist, Dabrafenib, Tafinlar, INCB039110, Itacitinib
Massachusetts General Hospital, Incyte Corporation
Melanoma
07/19
12/19
NCT02015117: Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases

Active, not recruiting
1
10
US
Laboratory Biomarker Analysis, Pharmacological Study, Therapeutic Conventional Surgery, Trametinib, GSK 1120212, GSK 212, GSK-1120212, GSK-212, GSK1120212, GSK212, JTP 74057, JTP-74057, JTP74057, MEK Inhibitor GSK1120212, Whole-Brain Radiotherapy, WBRT, whole-brain radiation therapy
National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Brain
07/20
09/24
NCT03299088: Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

Active, not recruiting
1
15
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
University of California, Davis, Merck Sharp & Dohme LLC, Novartis, National Cancer Institute (NCI)
KRAS Gene Mutation, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
01/21
06/24
NCT01740648: Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer

Completed
1
19
US
trametinib, GSK1120212, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, radiation therapy, irradiation, radiotherapy, therapy, radiation
Ohio State University Comprehensive Cancer Center, National Comprehensive Cancer Network, Novartis Pharmaceuticals
Recurrent Rectal Cancer, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
09/21
09/21
NCT03091257: A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

Recruiting
1
30
US
Dabrafenib, Tafinlar, Trametinib, Mekinist
Massachusetts General Hospital, Novartis, Multiple Myeloma Research Consortium, Barbara Ann Karmanos Cancer Institute
Multiple Myeloma
09/24
09/24
SJDAWN, NCT03434262: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Completed
1
68
US
Gemcitabine, Gemzar®, ribociclib, LEE011, LEE-011, KISQALI®, sonidegib, LDE225, LDE-225, ODOMZO®, trametinib, TMT212, TMT-212, MEKINIST(TM), filgrastim, G-CSF
St. Jude Children's Research Hospital, Novartis Pharmaceuticals
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
09/22
05/24
EATON, NCT03516214: EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations

Completed
1
18
Europe
EGF816, Nazartinib, Trametinib, Mekinist
University of Cologne
Bronchial Neoplasms
09/22
11/23
TOMIR, NCT05616923: Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea

Completed
1
12
US
Trametinib, MAPK inhibitor
Albany Research Institute, Inc.
Rosacea, Erythematotelangiectatic
12/22
12/22
NCT04967079: Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients

Completed
1
33
RoW
Trametinib, Anlotinib
Shanghai Chest Hospital
Non Small Cell Lung Cancer
07/23
03/24
NCT04303403: Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma

Recruiting
1
48
RoW
Trametinib, Mekinist, Ruxolitinib, Jakafi
National Cancer Centre, Singapore
Colorectal Cancer, Pancreatic Adenocarcinoma
06/23
03/24
NCT02070549: Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction

Active, not recruiting
1
46
Canada, US
Trametinib, GSK 1120212, GSK 212, GSK-1120212, GSK-212, GSK1120212, GSK212, JTP 74057, JTP-74057, JTP74057, MEK Inhibitor GSK1120212
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Solid Neoplasm, Unresectable Solid Neoplasm
08/23
11/24
ChiCTR2200063316: Phase IB clinical study on the tolerance, safety and efficacy of darafenib, trametinib combined with irinotecan and cetuximab in advanced colorectal cancer with BRAF mutation

Not yet recruiting
1
18
 
Darafenitumertinib plus iritiniconcetuximab
Sichuan Cancer Hospital; Sichuan Cancer Hospital, None
colorectal cancer
 
 
TRAHD, NCT03714958: Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type

Completed
1
12
Europe
HDM201, Trametinib
Centre Leon Berard, Novartis
Colorectal Cancer, Advanced Cancer, Metastatic Cancer
09/23
09/23
NCT03501368: Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

Active, not recruiting
1
27
US
Ceritinib, ZYKADIA, Trametinib, MEKINIST
H. Lee Moffitt Cancer Center and Research Institute, Novartis Pharmaceuticals
Melanoma, Unresectable Melanoma, Advanced Melanoma
10/22
08/24
NCT03317119: Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery

Completed
1
26
US
Laboratory Biomarker Analysis, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist, Trifluridine and Tipiracil Hydrochloride, Lonsurf, TAS 102, TAS-102, Tipiracil Hydrochloride Mixture with Trifluridine, Trifluridine/Tipiracil, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
City of Hope Medical Center, National Cancer Institute (NCI)
Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Carcinoma, RAS Family Gene Mutation, Stage III Colon Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7, Stage IIIA Colon Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Colon Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Colon Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7, Stage IV Colon Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Rectal Cancer AJCC v7, Stage IVA Colon Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Colon Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7
07/23
07/23
NCT03026517: Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma

Active, not recruiting
1
18
US
Dabrafenib, Trametinib, Phenformin
Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, Weill Medical College of Cornell University
Melanoma
01/25
01/25
THREAD, NCT03825289: Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer

Recruiting
1
39
US
Hydroxychloroquine, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
University of Utah, Novartis Pharmaceuticals
Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unresectable Pancreatic Carcinoma
01/25
01/26
NCT04111458: A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

Active, not recruiting
1
71
Europe, US
BI 1701963, Trametinib
Boehringer Ingelheim
Solid Tumors, KRAS Mutation; SOS1
10/24
10/24
NCT02974725: A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Terminated
1
241
Europe, US, RoW
LXH254, LTT462, Trametinib, Ribociclib
Novartis Pharmaceuticals
Non-Small Cell Lung Cancer, Melanoma
04/24
04/24
NCT04454476: Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor

Active, not recruiting
1
15
Japan
Trametinib treatment, Endoscopy
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Gastric Cancer, Metaplasia, Stage I Gastric Cancer, Initial-onset Gastric Cancer
05/24
05/25
NCT04294160: A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

Active, not recruiting
1
122
Europe, Canada, US, RoW
Dabrafenib, DRB436, Tafinlar, LTT462, Trametinib, TMT212, Mekinist, LXH254, TNO155, Spartalizumab, PDR001, Tislelizumab, VDT482, BGBA317
Novartis Pharmaceuticals
BRAF V600 Colorectal Cancer
10/24
10/24
NCT04965220: HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors

Recruiting
1
220
RoW
HLX 208, trametinib
Shanghai Henlius Biotech
Solid Tumor
06/24
06/25
NCT03085056: Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

Active, not recruiting
1
13
US
Trametinib, Paclitaxel
Memorial Sloan Kettering Cancer Center, Novartis
Anaplastic Thyroid Cancer
09/25
09/25
NCT03333343: Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Active, not recruiting
1
105
Europe, Canada, RoW
EGF816, trametinib, ribociclib, LXH254, INC280, gefitinib
Novartis Pharmaceuticals
EGFR-mutant Non-small Cell Lung Cancer
12/24
12/24
NCT05048134: A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies

Recruiting
1
345
RoW
HRS2300, HRS2300、 SHR-1316, HRS2300、SHR-1701, HRS2300、trametinib, HRS2300、Almonertinib
Jiangsu HengRui Medicine Co., Ltd.
Advanced Malignancies
01/25
03/25
NCT05440942: Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting
1
35
US
Trametinib, GSK1120212, TMT212-NXA, Mekinist, Ruxolitinib, INCB018424, INC424, Retifanlimab, INCMGA00012
Peter Hosein, MD, Incyte Corporation, Novartis Pharmaceuticals, University of Miami Sylvester Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma
03/25
09/27
NCT03975231: Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Recruiting
1
6
US
Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436A, GSK2118436, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
City of Hope Medical Center, National Cancer Institute (NCI)
BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma
04/25
04/25
SMMART, NCT03878524: Serial Measurements of Molecular and Architectural Responses to Therapy () PRIME Trial

Terminated
1
2
US
Abemaciclib, LY-2835219, LY2835219, Verzenio, Abiraterone, CB 7598, Afatinib, BIBW 2992, BIBW2992, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Zirabev, Anti-VEGF Monoclonal Antibody SIBP04, SIBP 04, SIBP-04, SIBP04, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Biospecimen Collection, Biological Sample Collection, Specimen Collection, Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Cabozantinib, Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Celecoxib, Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, Celebrex, SC-58635, YM 177, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, 934660-93-2, Copanlisib, BAY 80-6946, PI3K Inhibitor BAY 80-6946, Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Dacomitinib, EGFR Inhibitor PF-00299804, PF-00299804, PF-00299804-03, PF-299804, Vizimpro, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, 1297538-32-9, Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, 1428935-60-7, Enasidenib, AG-221, CC-90007 Free Base, Entrectinib, Rozlytrek, RXDX 101, RXDX-101, RXDX101, Enzalutamide, ASP9785, MDV3100, Xtandi, Erlotinib, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Idelalisib, CAL-101, GS 1101, GS-1101, Phosphoinositide-3 Kinase Delta Inhibitor CAL-101, Zydelig, Imatinib, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080, Leucovorin, Folinic acid, Lorlatinib, 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-, Lorbrena, PF-06463922, Losartan, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Neratinib, (2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide, HKI 272, HKI-272, PB 272, PB-272, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Panobinostat, Faridak, LBH589, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pertuzumab, 2C4, 2C4 Antibody, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, HLX11, Ponatinib, AP-24534, AP24534, Quality-of-Life Assessment, Quality of Life Assessment, Regorafenib, BAY 73-4506, REGORAFENIB ANHYDROUS, Stivarga, Ruxolitinib, INCB-18424, INCB18424, Jakafi, Oral JAK Inhibitor INCB18424, Sirolimus, AY 22989, RAPA, Rapamune, Rapamycin, SILA 9268A, WY-090217, Sorafenib, BA4 43 9006, BAY 43-9006, Bay-439006, Sunitinib, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Tretinoin, 2,4,6,8-Nonatetraenoic acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-, Aberel, Airol, Aknoten, all trans-Retinoic acid, All-trans Retinoic Acid, All-trans Vitamin A Acid, all-trans-Retinoic acid, all-trans-Vitamin A acid, ATRA, Avita, beta-Retinoic Acid, Cordes Vas, Dermairol, Epi-Aberel, Eudyna, Renova, Retin-A, Retin-A MICRO, Retin-A-Micro, Retinoic Acid, Retisol-A, Ro 5488, Stieva-A, Stieva-A Forte, Trans Retinoic Acid, Trans Vitamin A Acid, trans-Retinoic Acid, Tretinoinum, Vesanoid, Vitamin A Acid, Vitamin A acid, all-trans-, Vitinoin, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
OHSU Knight Cancer Institute, Oregon Health and Science University
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
12/20
12/20
SEACRAFT-1, NCT05907304: A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

Recruiting
1
115
Europe, Canada, US, RoW
Naporafenib, LXH254, ERAS-254, Trametinib, Mekinist
Erasca, Inc.
Advanced or Metastatic Solid Tumors
07/25
11/25
NCI-2018-01218, NCT03065387: Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Active, not recruiting
1
93
US
Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Neratinib, (2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide, HKI 272, HKI-272, PB 272, PB-272, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, EGFR Gene Amplification, EGFR Gene Mutation, ERBB2 Gene Amplification, ERBB2 Gene Mutation, ERBB3 Gene Mutation, ERBB4 Gene Mutation, KRAS Gene Mutation, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
10/25
10/25
Mel61, NCT02382549: A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib

Terminated
1
8
US
BRAF inhibitor, 6MHP, 6 melanoma helper peptide vaccine, MEK inhibitor
Craig L Slingluff, Jr, National Cancer Institute (NCI)
Melanoma
02/22
02/22
CodeBreak101, NCT04185883: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Checkmark Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Checkmark Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Sep 2022 - Sep 2022: Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Checkmark Presentation of data from CodeBreak 101 and CodeBreak 100 in combination with Keytruda and Tecentriq for 2L NSCLC at IASLC-WCLC 2022
More
Recruiting
1
1200
Europe, Canada, Japan, US, RoW
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Amgen
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
12/26
12/27
NCT05435846: Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

Terminated
1
3
US
Capmatinib, INC280, Trametinib, TMT212, Mekinist
Collin Blakely, Novartis
Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer
11/23
05/24
NCT04903119: Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma

Recruiting
1
15
US
Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg, Nilotinib 400mg, Dabrafenib, Trametinib
Ruta Arays, Novartis, National Cancer Institute (NCI)
Metastatic Melanoma, BRAF Gene Mutation
12/26
03/27
NCT04485559: Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

Recruiting
1
50
US
Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
University of California, San Francisco, Novartis Pharmaceuticals, Pediatric Brain Tumor Foundation, The Lilabean Foundation for Pediatric Brain Cancer Research
Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High Grade Glioma
12/27
12/27
NCT02357446: An Open Protocol for the Compassionate Use of Trametinib

Temporarily Not Available
N/A
Europe, RoW
Trametinib, Mekinist
Cancer Centre of Monoclonal Therapy, LLC, Melanoma Research Foundation, World Cancer Research Fund International, Worldwide Cancer Research
Cancer
 
 
NCT02416232 / 2014-005149-40: Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

No Longer Available
N/A
Europe
Trametinib, Dabrafenib
GlaxoSmithKline
Melanoma
 
 
NCT03386071: Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib

No Longer Available
N/A
NA
Trametinib 2 mg
Jonsson Comprehensive Cancer Center, Novartis
Progressive Metastatic Castrate Resistant Prostate Cancer
 
 
ChiCTR2100048697: Molecular phenotype study of advanced refractory solid tumors and exploratory clinical trials of PDX model construction

Completed
N/A
124
 
ARP inhibitor based combination therapy ;Trametinib based combination therapy ;Everolimus based combination therapy ;Combination therapy
The Second Hospital of Tianjin Medical University; The Second Hospital of Tianjin Medical University, No funds
Refractory solid tumor
 
 
NCT05806268: Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients

Completed
N/A
214
US
Novartis Pharmaceuticals
BRAF v600 Mutated Metastatic Melanoma
03/22
03/22
NCT05848219: Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib

Terminated
N/A
543
US
Novartis Pharmaceuticals
Metastatic Melanoma
04/22
04/22
NCT06337617: A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma

Completed
N/A
90
RoW
Novartis Pharmaceuticals
BRAF V600 Mutation Positive Melanoma
06/23
06/23
NCT04547946: Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)

Completed
N/A
3
Europe
dabrafenib + trametinib
Novartis Pharmaceuticals
Malignant Melanoma
06/22
06/22
ChiCTR2000035322: Optimization of standardized diagnosis and treatment system of melanoma in Chinese population

Not yet recruiting
N/A
40
 
Dabrafenib in Combination Trametinibwith
Shanghai Skin Disease Hospital; Shanghai Hospital Development Center, Shanghai Hospital Development Center
Melanoma
 
 
TAILOR, NCT04801966: Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

Terminated
N/A
3
RoW
Trametinib, Cobimetinib, Binimetinib, Alpelisib, Vemurafenib, Dabrafenib, Encorafenib, Palbociclib, Olaparib, Ribociclib, Abemaciclib, Talazoparib, Nivolumab, Atezolizumab, Pembrolizumab
Peter MacCallum Cancer Centre, Australia
Cancer
12/22
12/22
NCT03593993: A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas

Terminated
N/A
3
US
Surgical Cohort
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Musella Foundation
Glioma, BRAF V600E, Pleomorphic Xantho-Astrocytoma, Glioblastoma
07/23
07/23
NCT04507919: Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer

Available
N/A
NA
Dabrafenib, twice daily (BID), Trametininb, once daily (QD)
Novartis Pharmaceuticals
Small Cell Lung Carcinoma
 
 
RATIONALE, NCT05171374: pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE

Recruiting
N/A
500
RoW
Dabrafenib, Trametinib
MelanomaPRO, Russia, Novartis
Melanoma Stage III, Melanoma Stage IV, Melanoma
09/23
09/24
NCT04489433: Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

Available
N/A
NA
Dabrafenib and Trametinib, Dabrafenib, Trametinib
Novartis Pharmaceuticals
Melanoma
 
 
NCT04544202: Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

Available
N/A
NA
Dabrafenib and Trametinib, Dabrafenib, Trametinib
Novartis Pharmaceuticals
Melanoma, Adjuvant
 
 
LEAD Melanoma, NCT04961619: Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.

Recruiting
N/A
84
RoW
dabrafenib, trametinib
Novartis Pharmaceuticals
Melanoma
12/24
12/24
Combi-EU, NCT03944356: BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients

Active, not recruiting
N/A
232
Europe
Dabrafenib and Trametinib, Tafinlar and Mekinist
EuMelaReg gGmbH
Melanoma
12/23
06/24
NCT06262919: Special Drug Use-results Surveillance of Tafinlar/Mekinist

Recruiting
N/A
90
Japan
Tafinlar/Mekinist, Dabrafenib/trametinib
Novartis Pharmaceuticals
BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
12/31
12/31
OCEANMIST, NCT05260684: Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US

Completed
N/A
1
US
Encorafenib, Administration route: Oral, Binimetinib, Vemurafenib, Cobimetinib, Dabrafenib, Trametinib
Pfizer
Melanoma
12/23
12/23
NCT04666272: Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection

Recruiting
N/A
80
RoW
dabrafenib, trametinib
Novartis Pharmaceuticals
Melanoma
07/29
07/29
NCT05868629: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Recruiting
N/A
40
US
Non-investigational
Novartis Pharmaceuticals
Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
02/28
02/28
CA209-7PG, NCT05432622: A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy

Completed
N/A
95
US
Bristol-Myers Squibb
Melanoma
04/23
07/23
 

Download Options